Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis

Oncotarget

Volumn 6, Issue 12, 2015, Pages 9908-9923

  de Simone, Veronica ^a   Ronchetti, Giulia ^a   Franzè, Eleonora ^a   Colantoni, Alfredo ^a   Ortenzi, Angela ^a   Fantini, Massimo C ^a   Rizzo, Angelamaria ^a   Sica, Giuseppe S ^a   Sileri, Pierpaolo ^a   Rossi, Piero ^a   MacDonald, Thomas T ^b   Pallone, Francesco ^a   Monteleone, Giovanni ^a   Stolfi, Carmine ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apcmin + mice; COX 2 PGE2; STAT3; VEGF

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 6; PROSTAGLANDIN E2; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ALPHA INTERFERON; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER SIZE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARCINOGENESIS; CELL GROWTH; CELL TRANSFORMATION; COLON TUMOR; HT-29 CELL LINE; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; INFLAMMATION; INTERFERON-ALPHA; INTERLEUKINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84929590468     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3532     Document Type: Article

References (45)

1. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-767.
2. Monteleone G, Pallone F and Stolfi C. The dual role of inflammation in colon carcinogenesis. Int J Mol Sci. 2012; 13(9):11071-11084.
3. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer cell. 2009; 15(2):103-113.
4. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W, Jr., Murphy AJ, Valenzuela DM, Yancopoulos GD, Booth CJ, Cho JH, Ouyang W, Abraham C, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 2012; 491(7423):259-263.
5. Hyun YS, Han DS, Lee AR, Eun CS, Youn J and Kim HY. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis. 2012; 33(4):931-936.
6. Jauch D, Martin M, Schiechl G, Kesselring R, Schlitt HJ, Geissler EK and Fichtner-Feigl S. Interleukin 21 controls tumour growth and tumour immunosurveillance in colitisassociated tumorigenesis in mice. Gut. 2011; 60(12):1678-1686.
7. Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, Harrison O and Powrie F. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013; 210(5):917-931.
8. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C and Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118(2):560-570.
9. Stolfi C, Rizzo A, Franze E, Rotondi A, Fantini MC, Sarra M, Caruso R, Monteleone I, Sileri P, Franceschilli L, Caprioli F, Ferrero S, MacDonald TT, Pallone F and Monteleone G. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med. 2011; 208(11):2279-2290.
10. De Simone V, Pallone F, Monteleone G and Stolfi C. Role of T17 cytokines in the control of colorectal cancer. Oncoimmunology. 2013; 2(12):e26617.
11. Spolski R and Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov. 2014; 13(5):379-395.
12. Sondergaard H and Skak K. IL-21: roles in immunopathology and cancer therapy. Tissue Antigens. 2009; 74(6):467-479.
13. Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN, Hagerman L, Walsh W and Eisenhauer EA. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol. 2012; 30(27):3396-3401.
14. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA and Hausman DF. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol. 2008; 26(12):2034-2039.
15. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M and Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007; 448(7152):484-487.
16. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM and Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007; 448(7152):480-483.
17. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C and Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res. 2011; 71(17):5601-5605.
18. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F and Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011; 71(4):1263-1271.
19. Grivennikov SI and Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010; 21(1):11-19.
20. Wei L, Laurence A, Elias KM and O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 2007; 282(48):34605-34610.
21. Yeste A, Mascanfroni ID, Nadeau M, Burns EJ, Tukpah AM, Santiago A, Wu C, Patel B, Kumar D and Quintana FJ. IL-21 induces IL-22 production in CD4+ T cells. Nat Commun. 2014; 5:3753.
22. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C and Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009; 30(3):377-386.
23. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O and Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000; 60(17):4705-4708.
24. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996; 87(5):803-809.
25. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R and Ferrara N. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A. 2007; 104(25):10625-10630.
26. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55(18):3964-3968.
27. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H and Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003; 101(7):2620-2627.
28. Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya S and Taketo MM. Cyclooxygenase 2-and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 2002; 62(2):506-511.
29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-1964.
30. Sarra M, Monteleone I, Stolfi C, Fantini MC, Sileri P, Sica G, Tersigni R, Macdonald TT, Pallone F and Monteleone G. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis. 2010; 16(8):1332-1339.
31. Blatner NR, Mulcahy MF, Dennis KL, Scholtens D, Bentrem DJ, Phillips JD, Ham S, Sandall BP, Khan MW, Mahvi DM, Halverson AL, Stryker SJ, Boller AM, Singal A, Sneed RK, Sarraj B, et al. Expression of RORgammat marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med. 2012; 4(164):164ra159.
32. Hiramatsu Y, Suto A, Kashiwakuma D, Kanari H, Kagami S, Ikeda K, Hirose K, Watanabe N, Grusby MJ, Iwamoto I and Nakajima H. c-Maf activates the promoter and enhancer of the IL-21 gene, and TGF-beta inhibits c-Maf-induced IL-21 production in CD4+ T cells. J Leukoc Biol. 2010; 87(4):703-712.
33. Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, Caprioli F, Del Vecchio Blanco G, Paoluzi OA, Macdonald TT, Pallone F and Monteleone G. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology. 2007; 132(1):166-175.
34. Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, Stolfi C, Cardolini I, Dottori M, Boirivant M, Pallone F, Macdonald TT and Monteleone G. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology. 2008; 134(4):1038-1048.
35. Yamane H and Paul WE. Early signaling events that underlie fate decisions of naive CD4(+) T cells toward distinct T-helper cell subsets. Immunol Rev. 2013; 252(1):12-23.
36. Fantini MC, Rizzo A, Fina D, Caruso R, Becker C, Neurath MF, Macdonald TT, Pallone F and Monteleone G. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol. 2007; 37(11):3155-3163.
37. Zhuo C, Xu Y, Ying M, Li Q, Huang L, Li D, Cai S and Li B. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. Immunol Res. 2015.
38. Erdman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG and Schauer DB. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res. 2005; 65(10):3998-4004.
39. Caprioli F, Sarra M, Caruso R, Stolfi C, Fina D, Sica G, MacDonald TT, Pallone F and Monteleone G. Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol. 2008; 180(3):1800-1807.
40. Carpenter RL and Lo HW. STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel). 2014; 6(2):897-925.
41. Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA and Griffioen AW. Angiostatic activity of the antitumor cytokine interleukin-21. Blood. 2008; 112(13):4940-4947.
42. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F and Monteleone G. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol. 2008; 75(3):668-676.
43. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F and Pallone F. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997; 112(4):1169-1178.
44. Issa AY, Volate SR, Muga SJ, Nitcheva D, Smith T and Wargovich MJ. Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model. Carcinogenesis. 2007; 28(9):1978-1984.
45. Becker C, Fantini MC, Wirtz S, Nikolaev A, Kiesslich R, Lehr HA, Galle PR and Neurath MF. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut. 2005; 54(7):950-954.